Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis
A legfontosabb adatok
- Ki végzi
- Guangzhou Institute of Respiratory Disease
- Hol
- Guangzhou (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 400 fő, tervezett
- Kezdés
- 2024. dec. 1.
- Várható befejezés
- 2027. jan. 1.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A vizsgált kezelések
- Observational Cohort Classification of Inflammatory Subtypes in Bronchiectasis
- A regiszteradat frissítve
- 2024. december 4.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek nem cisztás fibrózis okozta bronchiectasiájuk van, és az elmúlt 12 hónapban legalább 2 rosszabbodásuk volt. Köpetmintákat vizsgálnak, és később csatlakozhatnak a HSK31858 vizsgálathoz.
- Életkor
- 18 éves vagy idősebb, BMI értéke legalább 18,0 kg/m²
- Nem
- Minden nem csatlakozhat.
- A betegség stádiuma
- Mellkasi HRCT felvételen látható bronchiectasia egy vagy több tüdőlebenyben, amelyet orvos nem cisztás fibrózis okozta bronchiectasiaként megerősített, az elmúlt 12 hónapban legalább 2 tüdő-rosszabbodással, és legalább 12 hónapos várható túléléssel.
- Korábbi kezelés
- Ha tartós hörgtágító kezelésre van szükség, az adagnak és a kezelési tervnek legalább 3 hónapja stabilnak kell lennie. Aki korábban HSK31858-cal vagy más DPP1-gátlóval kezelt volt, nem csatlakozhat.
A részvétel fő kizáró okai
- Fő diagnózis COPD vagy asztma
- Cisztás fibrózis okozta bronchiectasia
- Jelenleg NTM tüdőfertőzés, allergiás bronchopulmonalis aspergillosis vagy tuberkulózis kezelése
- A szűrés előtti 4 héten belül a bronchiectasia rosszabbodása
- Terhesség vagy szoptatás
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥18 years and BMI≥18.0 kg/m\^2 at the time of signing the ICF
- Chest HRCT showed bronchiectasis affecting one or more lobes and was confirmed by a clinician as NCFBE(clinically characterized by chronic cough, expectoration and/or intermittent hemoptysis, with or without shortness of breath and respiratory failure). HRCT was considered effective if the patient had received HRCT in the same hospital within 12 months and screening HRCT is not necessary
- Have at least 2 pulmonary exacerbations in the past 12 months before Screening
- If long-term treatment with bronchodilators (long-acting β-agonists and/or long-acting muscarinic antagonists) is required, the dose and regimen should remain stable for at least 3 months before the screening visit and throughout the study period
- The estimated survival time ≥ 12 months
- Women must be post-menopausal, surgically sterile, or using highly effective contraception methods from Day 1 to at least 30 days after the last dose
- Males with female partners of childbearing potential must be using effective contraception from Day 1 to at least 90 days after the last dose
- Give their signed study informed consent to participate
Ki nem vehet részt
- Patients with severe pulmonary fibrosis such as lung destruction, pneumonectomy surgery history, and pneumoconiosis, as well as previous or existing decompensated stage of pulmonary heart disease
- Patients who had hemoptysis and required medical intervention within 4 weeks prior to screening(except for coughing up minorbloody streaks)
- Patients previously treated with HSK31858 or other DPP1 inhibitor products. 9. Subjects with uncontrolled hypertension (SBP ≥180 mmHg at rest and/or DBP ≥110 mmHg)
- Medications that may cause hyperkeratosis (e.g., tumor necrosis factor-α antagonists) within 4 weeks prior to screening
- Patients who have used a strong inducer or suppressor of CYP3A within 14 days or 5 half-lives of the first investigational drug (whichever is longer)
- Patients who had smoked an average of 10 cigarettes or more per day in the previous 1 year were screened
- Had received live attenuated vaccine within 30 days before randomization. 22. The investigators judged that there were other conditions that were not suitable for participation in the study
- Have a primary diagnosis of COPD or asthma as judged by the Investigator. 2. A history of malignancy (excluding cured basal cell carcinoma of the skin, carcinoma in situ, and papillary carcinoma of the thyroid gland. The patients who had survived lung cancer surgery for at least 5 years without antitumor therapy can enroll in the study ) within 5 years prior to screening or a history of antitumor therapy
- Have bronchiectasis due to CF (HRCT showed that the above lung diseases became predominant) as judged by the Investigator
- Currently being treated Non-tuberculous Mycobacterial (NTM) pulmonary infections, allergic bronchopulmonary aspergillosis, or tuberculosis (TB), or active and currently symptomatic infections caused by COVID-19, or have the history of bronchopulmonary aspergillosis
- Subjects with a history of liver disease or current treatment for liver disease during the screening period, including but not limited to acute or chronic hepatitis, cirrhosis or liver failure (except for mild to moderate non-alcoholic fatty liver disease)
- Active hepatitis B virus infection (hepatitis B surface antigen positive with HBV-DNA load above the lower limit of detection), active hepatitis C virus infection (HCV antibody positive with HCV-RNA load above the lower limit of detection), or known HIV infection or syphilis infection
- Any other unstable clinical condition, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, psychiatric, or major physiological dysfunction, that the investigator considers to be (a) likely to affect patient safety throughout the study; (b) Influence the results of the study and its interpretation; (c) impeding the patient\'s ability to complete the entire study
- Subjects with uncontrolled type 1 or type 2 diabetes (fasting plasma glucose \>7.0 mmol/L)
- Laboratory tests during the screening period meet the following conditions: AST>2.0×ULN or ALT>2.0×ULN or TBIL>1.5×ULN eGFR\<60ml/min/1.73m2 Hb<90 g/L WBC <3×109 /L PLT <70×109 /L INR>1.5ULN,PT>ULN+3s, or APTT>ULN+10s. 15. Had participated in a clinical trial of any other drug or medical device in the 3 months prior to the screening (a drug or medical device treated with a clinical trial) or the subject had not been more than 5 half-lives from the last clinical trial of the drug at the time of screening
- Patients who had experienced any degree of acute exacerbation of bronchiectasis or were developing an acute exacerbation of bronchiectasis before 4 weeks of screening
- Pregnancy and lactation. 20. The subjects were unable to complete the questionnaires due to their limited educational level, or the subjects and their families failed to fill in the subjects\' log cards
Helyszínek itt: Kína
- The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, KínaContact: Guan Wei JieToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is an observational, multicenter study aimed at investigating the inflammation phenotypes in sputum samples from patients with non-cystic fibrosis bronchiectasis (NCFBE). The study will observe and classify these phenotypes during the clinical screening phase without any intervention. Patients enrolled in this study may later participate in the HSK31858 clinical trial, where they will receive treatment as part of the trial protocol. After the unblinding of the trial, the study will analyze the relationship between sputum inflammation phenotypes and clinical outcomes, including treatment response and prognosis. The goal is to develop a clinical prediction model that incorporates inflammation subtypes to better predict patient outcomes in bronchiectasis.
A vizsgálat 4 csoportja
- Inflammatory Subtype A
Participants classified under this inflammatory subtype based on sputum analysis will be observed without any intervention during the observational phase.
Kezelés: Observational Cohort Classification of Inflammatory Subtypes in Bronchiectasis
- Inflammatory Subtype B
Participants classified under this inflammatory subtype based on sputum analysis will be observed without any intervention during the observational phase.
Kezelés: Observational Cohort Classification of Inflammatory Subtypes in Bronchiectasis
- Inflammatory Subtype C
Participants classified under this inflammatory subtype based on sputum analysis will be observed without any intervention during the observational phase.
Kezelés: Observational Cohort Classification of Inflammatory Subtypes in Bronchiectasis
- Inflammatory Subtype D
Participants classified under this inflammatory subtype based on sputum analysis will be observed without any intervention during the observational phase.
Kezelés: Observational Cohort Classification of Inflammatory Subtypes in Bronchiectasis
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multicenter, Observational Study to Investigate Sputum Inflammation Phenotyping and Predict Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis, with Subsequent Participation in the HSK31858 Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2024. december 4.